Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fractyl Health Inc (GUTS)

Fractyl Health Inc (GUTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Fractyl Health Reports Successful Delivery of RJVA-001 in Yucatan Pig Models, Paving the Way for First-in-Human Studies in 2025

RJVA-001 demonstrated effective pancreatic targeting and GLP-1 expression with no safety issues in Yucatan pigs, supporting human trials in 2025.Quiver AI SummaryFractyl Health, Inc. has successfully delivered...

GUTS : 2.20 (+3.29%)
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

GUTS : 2.20 (+3.29%)
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

GUTS : 2.20 (+3.29%)
Fractyl Health to Participate in the Upcoming December Conferences

GUTS : 2.20 (+3.29%)
Why This Penny Stock Lost 13% Last Week While Markets Soared

Traders sold the news on this biotech stock's conference update.

GUTS : 2.20 (+3.29%)
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

GUTS : 2.20 (+3.29%)
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

GUTS : 2.20 (+3.29%)
Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024

GUTS : 2.20 (+3.29%)
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

GUTS : 2.20 (+3.29%)
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

GUTS : 2.20 (+3.29%)

Barchart Exclusives

Confused About Carvana (CVNA)? Try an Overlooked Long Iron Condor Trade.
After a blistering run from single-digit territory in late 2022, CVNA stock appears to have finally met its match. Here’s how to play the game moving forward. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar